Key result
Guidelines recommend individualizing glycemic targets and drug selection in type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Consensus review highlights individualized glycemic targets and cardiovascular risk reduction in type 2 diabetes, indicating the need for tailored therapeutic regimens.
Despite the advances in diabetes management, people with diabetes are not reaching their target glycemic goals. Healthcare professionals often fail to initiate, escalate, or de-intensify therapy when indicated. There are several organizations that provide guidance on the management of diabetes to assist the practitioner in achieving improved glycemic control, and this can cause confusion to the practitioner on which organizations' guidance to follow. Diabetes mellitus is associated with an elevated risk of cardiovascular disease, and there have been studies that suggest some antidiabetic medications increase cardiovascular risk and some reduce cardiovascular risk. Diabetes organizations recommend the individualization of treatment goals and choices of drug therapy that will be safe and effective. Healthcare professionals should be knowledgeable and equipped to decide on the best treatment regimen for each of their patients with type 2 diabetes (T2D) and be familiar with how to utilize the different organizations' philosophies in treating their patients.
No takes yet. Share an insight, caveat, or question.
Quattrocchi et al. (2020) conducted a review in Type 2 diabetes. Antidiabetic medications and consensus guideline management was evaluated. Diabetes organizations recommend individualizing glycemic goals and drug therapy choices in type 2 diabetes to balance efficacy, safety, and cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: